GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little evidence of improving cardiorespiratory fitness, researchers say.

CLEVELAND - A new study published by Cleveland Clinic researchers investigating the genetic underpinnings of weight loss response has identified a ...

Everyone aspires to live a healthy life. The catch is that health is a moving target. It’s a challenge that changes as people ...

More data, this time from a large observational study, are bolstering the idea that glucagon-like peptide-1 (GLP-1) receptor ...

Healthcare professionals are calling for a fundamental shift in public perception around medically supervised weight loss ...

Kenya’s healthcare system is witnessing a quiet transformation with the introduction of newer therapies for managing Type 2 ...

A new study published by Cleveland Clinic researchers in Diabetes, Obesity and Metabolism investigating the genetic ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

I have lost 3st (19kg) in six months with Mounjaro injections, but I've noticed my hair is getting much thinner. Is there ...

Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide.

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

Engineers at Georgia Tech developed a new mode of delivery for injectable medications — an 'exploding' capsule.